Evaluating the Effect of Utrogestan on Idiopathic Intrauterine Growth Retardation

Background: Intrauterine growth factor (IUGR) is one of the most important causes of neonatal mortality. The aim of this study was to evaluate the therapeutic effect of utrogestan on the treatment of IUGR and its complications. Materials and Methods: In this clinical trial, 66 pregnant women with id...

Full description

Bibliographic Details
Main Authors: Belgheis Mohammadi, Marzieh Matinfar, Fatemeh Drees, Sheida Shabanian
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2020-01-01
Series:Advanced Biomedical Research
Subjects:
Online Access:http://www.advbiores.net/article.asp?issn=2277-9175;year=2020;volume=9;issue=1;spage=45;epage=45;aulast=Mohammadi
_version_ 1828763055963504640
author Belgheis Mohammadi
Marzieh Matinfar
Fatemeh Drees
Sheida Shabanian
author_facet Belgheis Mohammadi
Marzieh Matinfar
Fatemeh Drees
Sheida Shabanian
author_sort Belgheis Mohammadi
collection DOAJ
description Background: Intrauterine growth factor (IUGR) is one of the most important causes of neonatal mortality. The aim of this study was to evaluate the therapeutic effect of utrogestan on the treatment of IUGR and its complications. Materials and Methods: In this clinical trial, 66 pregnant women with idiopathic IUGR embryos were enrolled. Patients in the intervention group, in addition to receiving routine treatment of control group (high-protein diet, resting), took utrogestan capsules (100 mg) twice daily. The primary and secondary outcomes of the disease were recorded in a checklist. Data were analyzed using SPSS 18 using an independent t-test, Chi-square test, and Fisher's exact test. Results: In the intervention group, mean neonatal weight (P = 0.003), mean neonatal Apgar score (P = 0.001), and mean gestational age at birth (P = 0.001) were significantly higher than those in the control group. There was no neonatal death in the intervention group, whereas in the control group, four cases of neonatal death were observed (P = 0.03). In the majority of subjects in the intervention group, resistance index, and pulsatility index of the umbilical artery decreased (P = 0.002). The difference in abdominal circumference and gestational age in the intervention group decreased (P = 0.01). In the intervention group, the diastolic flow of the umbilical artery increased (P = 0.002). Conclusion: Utrogestan was effective as an inexpensive and effective way to treat IUGR and improve pregnancy outcomes.
first_indexed 2024-12-11T01:54:52Z
format Article
id doaj.art-6fff04e19fda49a1a069c03c3d17bc9e
institution Directory Open Access Journal
issn 2277-9175
language English
last_indexed 2024-12-11T01:54:52Z
publishDate 2020-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Advanced Biomedical Research
spelling doaj.art-6fff04e19fda49a1a069c03c3d17bc9e2022-12-22T01:24:39ZengWolters Kluwer Medknow PublicationsAdvanced Biomedical Research2277-91752020-01-0191454510.4103/abr.abr_27_20Evaluating the Effect of Utrogestan on Idiopathic Intrauterine Growth RetardationBelgheis MohammadiMarzieh MatinfarFatemeh DreesSheida ShabanianBackground: Intrauterine growth factor (IUGR) is one of the most important causes of neonatal mortality. The aim of this study was to evaluate the therapeutic effect of utrogestan on the treatment of IUGR and its complications. Materials and Methods: In this clinical trial, 66 pregnant women with idiopathic IUGR embryos were enrolled. Patients in the intervention group, in addition to receiving routine treatment of control group (high-protein diet, resting), took utrogestan capsules (100 mg) twice daily. The primary and secondary outcomes of the disease were recorded in a checklist. Data were analyzed using SPSS 18 using an independent t-test, Chi-square test, and Fisher's exact test. Results: In the intervention group, mean neonatal weight (P = 0.003), mean neonatal Apgar score (P = 0.001), and mean gestational age at birth (P = 0.001) were significantly higher than those in the control group. There was no neonatal death in the intervention group, whereas in the control group, four cases of neonatal death were observed (P = 0.03). In the majority of subjects in the intervention group, resistance index, and pulsatility index of the umbilical artery decreased (P = 0.002). The difference in abdominal circumference and gestational age in the intervention group decreased (P = 0.01). In the intervention group, the diastolic flow of the umbilical artery increased (P = 0.002). Conclusion: Utrogestan was effective as an inexpensive and effective way to treat IUGR and improve pregnancy outcomes.http://www.advbiores.net/article.asp?issn=2277-9175;year=2020;volume=9;issue=1;spage=45;epage=45;aulast=Mohammadifetal growth retardationplacentautrogestan
spellingShingle Belgheis Mohammadi
Marzieh Matinfar
Fatemeh Drees
Sheida Shabanian
Evaluating the Effect of Utrogestan on Idiopathic Intrauterine Growth Retardation
Advanced Biomedical Research
fetal growth retardation
placenta
utrogestan
title Evaluating the Effect of Utrogestan on Idiopathic Intrauterine Growth Retardation
title_full Evaluating the Effect of Utrogestan on Idiopathic Intrauterine Growth Retardation
title_fullStr Evaluating the Effect of Utrogestan on Idiopathic Intrauterine Growth Retardation
title_full_unstemmed Evaluating the Effect of Utrogestan on Idiopathic Intrauterine Growth Retardation
title_short Evaluating the Effect of Utrogestan on Idiopathic Intrauterine Growth Retardation
title_sort evaluating the effect of utrogestan on idiopathic intrauterine growth retardation
topic fetal growth retardation
placenta
utrogestan
url http://www.advbiores.net/article.asp?issn=2277-9175;year=2020;volume=9;issue=1;spage=45;epage=45;aulast=Mohammadi
work_keys_str_mv AT belgheismohammadi evaluatingtheeffectofutrogestanonidiopathicintrauterinegrowthretardation
AT marziehmatinfar evaluatingtheeffectofutrogestanonidiopathicintrauterinegrowthretardation
AT fatemehdrees evaluatingtheeffectofutrogestanonidiopathicintrauterinegrowthretardation
AT sheidashabanian evaluatingtheeffectofutrogestanonidiopathicintrauterinegrowthretardation